A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells

Nature Medicine

Volumn 22, Issue 7, 2016, Pages 812-821

  Reinisch, Andreas ^a,b   Thomas, Daniel ^a,b   Corces, M Ryan ^a,b   Zhang, Xiaohua ^a,b   Gratzinger, Dita ^a   Hong, Wan Jen ^a,b   Schallmoser, Katharina ^c   Strunk, Dirk ^c   Majeti, Ravindra ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; PARATHYROID HORMONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER MODEL; CANCER STEM CELL; CELL DIFFERENTIATION; CHIMERA; COLONY FORMING UNIT GM; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMANIZED BONE MARROW OSSICLE XENOTRANSPLANTATION; LEUKEMIA CELL; LEUKEMIA INITIATING CELL; MEGAKARYOCYTE ERYTHROID PROGENITOR; MESENCHYMAL STROMA CELL; MOUSE; MYELOFIBROSIS; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; STEM CELL NICHE; TUMOR MICROENVIRONMENT; UMBILICAL CORD BLOOD; XENOTRANSPLANTATION; ACUTE MYELOID LEUKEMIA; ANIMAL; BONE; BONE TRANSPLANTATION; CANCER TRANSPLANTATION; DISEASE MODEL; FETUS BLOOD; HEMATOPOIETIC STEM CELL; MYELOID METAPLASIA; SCID MOUSE; XENOGRAFT;

ANIMALS; BONE AND BONES; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; BONE TRANSPLANTATION; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; FETAL BLOOD; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MESENCHYMAL STROMAL CELLS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PRIMARY MYELOFIBROSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT;

EID: 84969847331     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4103     Document Type: Article

References (56)

1. Doulatov, S., Notta, F., Laurenti, E. and Dick, J.E. Hematopoiesis: a human perspective. Cell Stem Cell 10, 120-136 (2012).
2. Wunderlich, M. et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24, 1785-1788 (2010).
3. Nicolini, F.E., Cashman, J.D., Hogge, D.E., Humphries, R.K. and Eaves, C.J. NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration. Leukemia 18, 341-347 (2004).
4. Rongvaux, A. et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32, 364-372 (2014).
5. Willinger, T. et al. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc. Natl. Acad. Sci. USA 108, 2390-2395 (2011).
6. Goyama, S., Wunderlich, M. and Mulloy, J.C. Xenograft models for normal and malignant stem cells. Blood 125, 2630-2640 (2015).
7. Sarry, J.E. et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J. Clin. Invest. 121, 384-395 (2011).
8. Sanchez, P.V. et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 23, 2109-2117 (2009).
9. Patel, S. et al. Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2Rγ-/- mice. Leukemia 26, 2432-2435 (2012).
10. Kim, D., Park, C.Y., Medeiros, B.C. and Weissman, I.L. CD19-CD45low/- CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 26, 2530-2537 (2012).
11. Kim, D. et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26, 2538-2545 (2012).
12. Pang, W.W. et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc. Natl. Acad. Sci. USA 110, 3011-3016 (2013).
13. Medyouf, H. et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 14, 824-837 (2014).
14. Mendelson, A. and Frenette, P.S. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat. Med. 20, 833-846 (2014).
15. Ishikawa, F. et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25, 1315-1321 (2007).
16. Schepers, K., Campbell, T.B. and Passegue, E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell 16, 254-267 (2015).
17. Reinisch, A. et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood 125, 249-260 (2015).
18. Saito, Y. et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med. 2, 17ra9 (2010).
19. Song, J. et al. An in vivo model to study and manipulate the hematopoietic stem cell niche. Blood 115, 2592-2600 (2010).
20. Pettway, G.J. et al. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone 36, 959-970 (2005).
21. Zhang, J. et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841 (2003).
22. Klco, J.M. et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25, 379-392 (2014).
23. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
24. Bonnet, D. and Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737 (1997).
25. Grimwade, D. and Enver, T. Acute promyelocytic leukemia: where does it stem from? Leukemia 18, 375-384 (2004).
26. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005).
27. Baxter, E.J. et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005).
28. Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379-2390 (2013).
29. Nangalia, J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369, 2391-2405 (2013).
30. James, C. et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 112, 2429-2438 (2008).
31. Ishii, T. et al. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp. Hematol. 35, 1633-1640 (2007).
32. Wang, X. et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J. Clin. Invest. 122, 3888-3899 (2012).
33. Dameshek, W. Some speculations on the myeloproliferative syndromes. Blood 6, 372-375 (1951).
34. Majeti, R., Park, C.Y. and Weissman, I.L. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 1, 635-645 (2007).
35. Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086-1093 (2011).
36. Goardon, N. et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19, 138-152 (2011).
37. Takatsuki, H. et al. PML/RARα fusion gene is expressed in both granuloid/macrophage and erythroid colonies in acute promyelocytic leukaemia. Br. J. Haematol. 85, 477-482 (1993).
38. Turhan, A.G. et al. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 85, 2154-2161 (1995).
39. Haferlach, T. et al. Cell lineage specific involvement in acute promyelocytic leukaemia (APL) using a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques for the detection of the translocation t(15;17)(q22;q12). Br. J. Haematol. 103, 93-99 (1998).
40. Knuutila, S. et al. Cell lineage involvement of recurrent chromosomal abnormalities in hematologic neoplasms. Genes Chromosom. Cancer 10, 95-102 (1994).
41. Guibal, F.C. et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 114, 5415-5425 (2009).
42. Brown, D. et al. A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94, 2551-2556 (1997).
43. Grignani, F. et al. PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 96, 1531-1537 (2000).
44. Matsushita, H. et al. Establishment of a humanized APL model via the transplantation of PML-RARA-transduced human common myeloid progenitors into immunodeficient mice. PLoS One 9, e111082 (2014).
45. Wang, X. et al. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood 116, 5972-5982 (2010).
46. Rongvaux, A. et al. Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. Proc. Natl. Acad. Sci. USA 108, 2378-2383 (2011).
47. Willinger, T., Rongvaux, A., Strowig, T., Manz, M.G. and Flavell, R.A. Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. Trends Immunol. 32, 321-327 (2011).
48. Groen, R.W. et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 120, e9-e16 (2012).
49. Alvarez, L.L. and Pardo, H.G. Guide for the care and use of laboratory animals - Natl-Res-Council. Psicothema 9, 232-234 (1997).
50. Rohde, E., Schallmoser, K., Bartmann, C., Reinisch, A and Dirk, S. in Pharmaceutical Manufacturing Handbook: Regulations and Quality (ed. Gad, S.C.) 97-115 (John Wiley and Sons, Inc., 2008).
51. Schallmoser, K. et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng. Part C Methods 14, 185-196 (2008).
52. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317 (2006).
53. Notta, F. et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 333, 218-221 (2011).
54. Moraga, I. et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell 160, 1196-1208 (2015).
55. Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. and Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl. Acad. Sci. USA 111, 2548-2553 (2014).
56. Boggs, D.R. The total marrow mass of the mouse: a simplified method of measurement. Am. J. Hematol. 16, 277-286 (1984).